Wells Fargo analyst Mohit Bansal lowered the firm’s price target on BioMarin (BMRN) to $70 from $90 and keeps an Overweight rating on the shares. The firm is lowering its estimates for Voxzogo significantly, as Wells thinks competitive uncertainty warrants conservatism. The firm sees near-term challenges but sees stock working toward back half of 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMRN:
- BioMarin price target lowered to $80 from $86 at Barclays
- BioMarin Reports Strong Q3 2025 Revenue Growth
- BioMarin Pharmaceutical: Strategic Adjustments and Future Potential Justify Buy Rating Despite Revenue Miss
- BioMarin’s BMN 349 Study: A New Hope for Alpha 1-Antitrypsin Deficiency
- BioMarin lowers 2025 non-GAAP EPS view to $3.50-$3.60 from $4.40-$4.55